Dr. Ullman has been with the company since 2002 and has served as chief scientific officer since 2009. He has been instrumental in developing Isogenica’s strategy and driving its technologies.
“Dr. Ullman has worked closely with Dr. Matthews over the last five years and has been at the heart of delivering a fundamental change in the capability and direction of the business. I am sure that Chris will be successful in further developing Isogenica to provide technologies and technology capabilities that are valued by its pharma and biotech partners and academic collaborators,” said Jan-Olof Lundin, Chairman of Isogenica.